MMP11 and Familial prostate cancer: The results of the TCGA data showed that there were statistical significant differences between the MMP-11 mRNA level and the patients with prostate cancer and normal controls (p < 0.0001), clinical T stage (p = 0.0051), pathological T stage (p < 0.0001), pathological N stage (p < 0.0001) and biochemical recurrence (p < 0.0001) (Figure 2).